CI — Cigna Corporation

Wall Street's sell side is clearly constructive - 28 Buy vs 11 Hold ratings, zero Sells, and a $338.33 consensus price target (range $302-$400) that sits ~20% above the 2026-09-13 price of $280.76. But the tape doesn't agree: as of 2026-09-13 the stock was down 5.79% over three months and 0.62% over the past week despite the July 30, 2026 Q2 beat ($71.7B revenue, +7% YoY; adjusted EPS $7.78 vs $7.60 consensus) and a raised full-year outlook of at least $30.45. Sentiment is therefore split - fundamentally bullish, technically indifferent. The market is applying a persistent PBM/regulatory discount and discounting the deliberate ACA Exchange exit at year-end 2026 rather than rewarding the beat-and-raise. That is a 'good news not moving the stock' pattern, which is characteristic of multiple compression rather than fundamental deterioration.

Revenue growth is decelerating but deliberately so. Quarterly revenue went $49.05B (Q3'23) -> $63.69B (Q3'24) -> $69.75B (Q3'25) -> $71.67B (Q2'26). YoY growth has slowed from double digits (Q2 2025 revenue of $67.23B vs Q2 2024's $60.52B, +11.1%) to mid-single digits (Q2 2026 $71.67B vs $67.23B, +6.6%), partly because management is exiting government risk-bearing programs (Medicare Advantage already, ACA Exchange at end of 2026). Earnings quality is trending the other way: diluted EPS went $5.45 (Q2'24) -> $5.71 (Q2'25) -> $6.29 (Q2'26), and Q1 2026 EPS of $6.26 nearly matched Q2 despite no seasonal tailwind, up from $4.85 in Q1 2025. Operating income of $2.676B in Q2 2026 was up ~10% YoY from $2.432B, so operating margin actually firmed slightly to 3.73% from 3.62% - it remains structurally thin (3.5% operating, 2.3% net margin on a TTM basis), which is normal for a business grossing up pass-through drug spend. One flag: Q2 2026 gross profit of $14.97B (20.9% of revenue) is a sharp jump from the prior three quarters ($6.47B, $5.55B, $5.94B; TTM gross margin 11.7%) with no matching jump in operating margin - that looks like a cost-line reclassification or one-off item, not durable gross-margin expansion, and I would not underwrite it until verified. Cash flow is heavily back-half weighted and lumpy: H1 2026 free cash flow was just $146M (Q1 +$864M, Q2 -$718M) versus full-year 2025 FCF of $8.39B and 2024's $8.96B. The Q2 2026 FCF loss of $718M is a real improvement on the -$2.17B in Q2 2025, but it is a seasonal pattern, not deterioration. Bottom line: revenue growth decelerating on purpose, earnings per share inflecting up, margin roughly flat, cash generation intact on an annual basis.

Cheap, both absolute and relative, with an asterisk. As of 2026-09-13 the TTM P/E was 11.58x versus a 5-year average TTM P/E of 16.34x - a ~29% discount to its own history - and P/S was 0.263 versus a 5-year average of 0.41, a ~36% discount. PEG of 0.366 and P/B of 1.74 are undemanding, and the 2.24% dividend yield is well covered by ~$9B of expected full-year operating cash flow. On the raised FY26 adjusted EPS floor of at least $30.45, the forward multiple is only ~9.2x. The honest caveat: some of this discount is structural, not a mispricing. The market has permanently re-rated PBM economics downward on regulatory risk, and Cigna is simultaneously shrinking its government risk book, so a return to 16x is not a reasonable base case. Even a partial re-rating to 11-12x forward adjusted earnings implies $335-$365, which is exactly where the sell-side targets cluster.

At $280.76 as of 2026-09-13, the stock is pricing roughly $30.50 of forward adjusted earnings at 9.2x - the market is essentially applying the worst-case PBM multiple to an earnings stream that management just raised. Note that 9.0x on $30.50 equals ~$275, so the current price is already sitting on the pessimistic-multiple case; you are not paying for a re-rating. Q2 2026 adjusted EPS of $7.78 beat the $7.60 consensus by $0.18, so estimates are being cleared, not missed. The crucial wrinkle: the GAAP-to-adjusted gap is wide and persistent (Q2 2026 GAAP diluted EPS $6.29 vs $7.78 adjusted, a ~$1.49 quarterly gap mostly from acquired-intangible amortization, roughly $6/year). That means TTM GAAP EPS of $24.31 may grow only modestly even as adjusted EPS climbs - if the market ever decides to value CI on GAAP earnings, the multiple looks far less cheap. The whole upside case is a multiple story (9x to 11x forward), not an earnings-surprise story; the whole downside case is that the PBM discount is permanent.

As of 2026-09-13, CI was dead-center neutral: RSI(14) of 50.26, price of $280.76 sitting +0.46% above its 20-day SMA, -0.96% below its 50-day SMA, and +0.38% above its 200-day SMA - pinned to all three moving averages within a one-percent band. That is textbook range-bound/coiling behavior, not a trend. Returns as of that date: -0.62% over one week, +1.21% over one month, -5.79% over three months, +5.08% over six months. With a beta of 0.317 and the stock in the lower-middle third of its $239.51-$315.47 52-week range, there is no oversold bounce setup and no breakout. Timing implication: nothing here forces a decision. A sustained move above the moving-average cluster and then $300 would be the first real evidence of a re-rating; a break below roughly $270 would put the low $250s back in play. Traders should wait for the range to resolve; longer-term buyers are not being punished for patience.

• PBM regulation is the single biggest macro swing factor: federal and state proposals on rebate transparency, spread pricing, and 'delinking' could compress Cigna's pharmacy economics. Cigna's preemptive lean into its transparent, rebate-free 'Signature' model is a partial hedge but does not eliminate headline risk.
• Interest rates and defensive rotation: with a beta of only 0.317 and a 2.24% dividend yield, CI behaves partly like a bond proxy. A falling-rate, late-cycle rotation into low-volatility defensives is a relative tailwind; a risk-on growth rotation is a relative headwind, which is one plausible explanation for the flat-to-down tape despite earnings beats.
• Employer health cost inflation: rising corporate medical cost trends are pushing employers toward integrated pharmacy-plus-medical management and analytics - structurally good for Evernorth - while simultaneously raising the risk that Cigna's own insured medical care ratio drifts above the 84.5% booked in Q2 2026.
• Specialty drug and biosimilar mix: specialty utilization and biosimilar adoption drove Evernorth's Specialty and Care Services pre-tax growth of 22% in Q2 2026, a genuine tailwind for Accredo, but the same specialty trend is a cost headwind on the insured book and a target for policymakers.
• ACA marketplace subsidy and risk-pool dynamics: Cigna's exit from the Exchange marketplace at year-end 2026 removes roughly a low-single-digit revenue contribution but also removes a volatile, policy-exposed risk pool - a margin-quality positive that shows up as a revenue-growth headwind in 2027.

• Q3 2026 earnings, expected late October / early November 2026: the first real read on 2027 pharmacy benefit client retention and the selling season, plus any further upward revision to the at-least-$30.45 FY26 adjusted EPS guidance.
• 2027 Evernorth selling-season visibility: retention rates and net new business wins as payers and employers adjust to rebate-free PBM structures - this is the metric that could force a multiple re-rating if it comes in strong.
• Completion of the ACA Exchange exit at end of 2026: a cleaner, higher-margin 2027 mix, at the cost of reported revenue growth.
• Capital return execution: roughly $9B of expected full-year operating cash flow, back-half weighted, funding aggressive buybacks at a ~9x forward earnings multiple - mechanically accretive to EPS if the multiple stays depressed.
• Any federal PBM rulemaking or legislative action, which could move the stock hard in either direction regardless of operating results.

• PBM regulatory action that compresses rebate economics, forces delinking, or otherwise reprices the pharmacy supply chain - the primary reason the multiple sits at 11.6x instead of the 16.34x 5-year average.
• Medical cost trend deterioration: Q2 2026's 84.5% medical care ratio was a positive, but a 100-200bp adverse move on a commercial risk book with only ~3.5% operating margins would hit earnings disproportionately.
• Concentration risk in Evernorth, which produced roughly $61.5B of Q2 2026's $71.7B total revenue - losing one or two large PBM clients during a renewal season would be materially dilutive and is largely outside management's control.
• The wide GAAP-to-adjusted earnings gap (~$6/share per year of amortization and other adjustments) means GAAP diluted EPS of $24.31 is barely growing even as adjusted EPS climbs; a market shift toward GAAP-based valuation would cap any re-rating.
• Cash flow lumpiness: H1 2026 operating cash flow was only $710M against a ~$9B full-year expectation, so the buyback-and-dividend story depends entirely on a very heavy H2. A miss there would pressure both capital returns and the balance sheet, which already carries $29.1B of long-term debt against $6.3B of cash and a 0.846 current ratio.

Cigna at $280.76 on 2026-09-13 is a cheap, low-beta cash machine whose earnings keep clearing the bar while its multiple keeps sinking - the price already embeds roughly 9x forward adjusted earnings, which is close to the pessimistic PBM case. That gives an asymmetric setup: modest earnings growth plus any multiple normalization toward 11x gets you to the mid-$330s, while the downside is largely a multiple that has already compressed. The offset is that this is a 'Fair Fundamentals' business, not a compounder - structurally thin 3.5% operating margins, lumpy quarterly cash flow, a wide GAAP-to-adjusted earnings gap, and a real, unresolved policy overhang on pharmacy economics. It is a reasonable value holding for a patient investor, not a stock with a near-term catalyst to force the re-rating.

Blended two independent methods as of 2026-09-13: (1) a justified forward P/E of 11.5x applied to forward adjusted EPS of $30.50 (roughly the company's raised FY26 guidance floor and the analyst next-FY average) = $350.75 - below the 16.34x five-year average TTM P/E to reflect the structural PBM regulatory overhang, but above the prevailing 9.2x forward to reflect the low 0.317 beta, 2.24% dividend, and ~$9B annual operating cash flow; and (2) 9.5x EV/EBITDA on approximately $11.45B of TTM EBITDA = ~$108.8B enterprise value, less ~$22.8B of net debt ($29.09B long-term debt less $6.30B cash) = ~$86.0B equity, divided by ~264M shares = $325.5. Averaging the two methodologies gives approximately $338 per share.